↓ Skip to main content

Clinical Pharmacogenetics Implementation Consortium Guidelines for Human Leukocyte Antigen-B Genotype and Allopurinol Dosing

Overview of attention for article published in Clinical Pharmacology & Therapeutics, October 2012
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (77th percentile)
  • Good Attention Score compared to outputs of the same age and source (65th percentile)

Mentioned by

twitter
4 tweeters
facebook
1 Facebook page
wikipedia
1 Wikipedia page

Citations

dimensions_citation
157 Dimensions

Readers on

mendeley
108 Mendeley
Title
Clinical Pharmacogenetics Implementation Consortium Guidelines for Human Leukocyte Antigen-B Genotype and Allopurinol Dosing
Published in
Clinical Pharmacology & Therapeutics, October 2012
DOI 10.1038/clpt.2012.209
Pubmed ID
Authors

M S Hershfield, J T Callaghan, W Tassaneeyakul, T Mushiroda, C F Thorn, T E Klein, M T M Lee

Abstract

Allopurinol is the most commonly used drug for the treatment of hyperuricemia and gout. However, allopurinol is also one of the most common causes of severe cutaneous adverse reactions (SCARs), which include drug hypersensitivity syndrome, Stevens–Johnson syndrome, and toxic epidermal necrolysis. A variant allele of the human leukocyte antigen (HLA)-B, HLA-B*58:01, associates strongly with allopurinolinduced SCAR. We have summarized the evidence from the published literature and developed peer-reviewed guidelines for allopurinol use based on HLA-B genotype.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 108 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Portugal 1 <1%
France 1 <1%
Unknown 106 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 14 13%
Student > Ph. D. Student 13 12%
Student > Bachelor 12 11%
Researcher 12 11%
Student > Doctoral Student 9 8%
Other 27 25%
Unknown 21 19%
Readers by discipline Count As %
Medicine and Dentistry 29 27%
Pharmacology, Toxicology and Pharmaceutical Science 21 19%
Agricultural and Biological Sciences 13 12%
Biochemistry, Genetics and Molecular Biology 10 9%
Unspecified 3 3%
Other 9 8%
Unknown 23 21%

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 October 2015.
All research outputs
#2,154,911
of 10,181,331 outputs
Outputs from Clinical Pharmacology & Therapeutics
#465
of 2,110 outputs
Outputs of similar age
#68,301
of 306,484 outputs
Outputs of similar age from Clinical Pharmacology & Therapeutics
#14
of 40 outputs
Altmetric has tracked 10,181,331 research outputs across all sources so far. Compared to these this one has done well and is in the 78th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,110 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one has done well, scoring higher than 77% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 306,484 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 77% of its contemporaries.
We're also able to compare this research output to 40 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.